Trevena
Biopharmaceutical company developing novel G protein-biased ligands for the treatment of serious central nervous system disorders, including pain management. Publicly traded on NASDAQ (TRVN).
Notes
Trevena is a biopharmaceutical company focused on developing novel G protein-biased ligands for the treatment of serious central nervous system (CNS) disorders. The company is publicly traded on NASDAQ under the ticker symbol TRVN and is headquartered in Chesterbrook, Pennsylvania.
G protein-biased ligands are a novel class of therapeutics that selectively activate beneficial signaling pathways while minimizing activation of pathways associated with side effects. This approach has particular promise for:
- Pain management (reducing opioid side effects)
- CNS disorders
- Other conditions where traditional receptor targeting has limitations
Trevena's lead product OLINVYK (oliceridine) is an FDA-approved IV opioid for moderate to severe acute pain in adults.
Team
- Carrie Bourdow - President & Chief Executive Officer
- LinkedIn: linkedin.com/in/carriebourdow
Additional Research Findings
- NASDAQ: TRVN (publicly traded)
- Portfolio company of Polaris Partners
- G protein-biased ligand technology
- FDA-approved product: OLINVYK (oliceridine)
- CNS disorders and pain management focus
- Chesterbrook, Pennsylvania headquarters
- Founded in 2007
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |